They evaluated the plasma and tissue levels of VEGF and HIF-1α and found that low VEGF and HIF-1α plasma levels were significantly associated with better treatment response and longer OS, whereas high expressions of VEGF and HIF in HCC tissue were linked to poor treatment outcomes and shorter OS (40). This evidence concerns the gene VEGFA and hepatocellular carcinoma.